SEATTLE, WA–(Marketwire – February 25, 2010) – Atossa Genetics, Inc., a privately-held healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer, including the FDA approved Mammary Aspirate Specimen Cytology Test (MASCT) System, announced today that Edward Sauter, M.D., Ph.D., associate dean for research at …

This entry was posted on Thursday, February 25th, 2010 at 10:12 pm and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.

---